In adults, Emtriva® should usually be administered orally at a dose of 200 mg of emtricitabine once daily. Emtriva® should be used in combination with other anti-HIV drugs.
5. Warning:
Sufficient caution should be exercised to patient with complication of chronic hepatitis B in case administration of Emtriva® is discontinued since exacerbation of chronic hepatitis B might be observed after discontinuation of Emtriva® administration. Especially, particular caution should be exercised to patient with complication of decompensated hepatitis B since decompensated hepatitis B might be aggravated.
6. Contraindications:
Patients with a previously demonstrated hypersensitivity to any of the components of the product.
7. Adverse Drug Reactions:
In two comparative clinical studies in foreign countries, 303 (52.5%) of 580 cases that received Emtriva® presented adverse drug reactions. The common adverse drug reactions were diarrhea, dizziness, nausea, abdominal pain, headache, insomnia, and asthenia etc. Clinically significant adverse drug reactions, including lactic acidosis, might occur.
